Hanns–Ulrich Marschall

Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist

Sama I. Sayin, Annika Wahlström, Jenny Felin et al. · Cell Metabolism · 2013 · 2.2K citations · Full text

Dysbiosis, Biochemistry, Biliary Tract +9

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

Olle Ringdén, Mehmet Uzunel, Ida Rasmusson et al. · Transplantation · 2006 · 1.1K citations

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Frederik Nevens, Pietro Andreoné, G. Mazzella et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal et al. · Gastroenterology · 2013 · 906 citations

Metabolic Syndrome, Hepatology, Nonalcoholic Fatty Liver Disease +9